Cardiac Complications of Pregnancy in Desmoplakin Cardiomyopathy.

We present the course of 4 pregnancies in 3 women with desmoplakin cardiomyopathy, with a focus on changes in left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels from the prepregnancy period through the postpartum period, as well as maternal cardiac, obstetric, and neonatal outcomes. (

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

This project was funded by the Linda J. Pollin Award and McKenzie Master Clinician Scholar Award at the Brigham and Women’s Hospital. The STORCC initiative was funded by the Brigham and Women's Hospital Watkins Discovery Award, the Weinberg Barton Family Fund, the Boston Adult Congenital Heart Disease Program Dunlevie Fund, and the Sarah Marie Liamos Fund for Adult Congenital Heart Disease Research. No sponsors had any involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Dr Valente has served on the advisory board for Practice Update. Dr Lakdawala has received unrestricted research support from Pfizer; and has received modest consulting income from Pfizer, Bristol-Myers Squibb, Tenaya, and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.